Navigation Links
Aegera Therapeutics welcomes two experienced executives to its board of directors
Date:4/24/2008

MONTREAL, April 24 /PRNewswire/ - Aegera Therapeutics Inc. is very pleased to announce the appointment of two experienced biotechnology and financial executives to its Board of Directors: Mr. Jeremy Curnock Cook, Executive Chairman and Founder of BioScience Managers Limited, and Mr. Gary Littlejohn, Managing Director of Desjardins Securities.

"Gary and Jeremy's extensive industry experience and networks will be critical for Aegera as we make key strategic decisions in support of the attainment of our corporate vision of becoming a profitable, public biotechnology company," commented Mr. James Rae, Chairman of the Board, Aegera Therapeutics Inc.

"I am extremely enthusiastic about joining Aegera's Board at such a critical and exciting time for the company," stated Mr. Curnock Cook. "Their recent clinical and business milestone achievements are very impressive by any measure and I look forward to working with management and the Board to assist the company in accelerating their efforts to achieve their very aggressive business plan."

"Aegera is one of Canada's premier biotechnology companies." added Mr. Littlejohn. "I look forward to working with the accomplished executive team to capitalize on their successes and to continue to build shareholder value both as a private and potentially as a public company."

Mr. Curnock Cook and Mr. Littlejohn join Aegera's existing Board consisting of the following members:

- Mr. James M. Rae, Chairman, President, Remedis Consulting

- Dr. Michael J. Berendt, President & CEO, Aegera Therapeutics

- Dr. Ines Holzbaur, Vice-President, GeneChem Management

- Mr. Serge Langford, Managing Partner, Multiple Capital

- Dr. Luc Marengere, Managing General Partner, Vengrowth Capital

Management

- Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital

- Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance, ConjuChem

The detailed biographies of Mr. Curnock Cook, Mr. Littlejohn and all of Aegera's Board Members can be viewed at http://www.aegera.com

About Aegera Therapeutics Inc.

Aegera Therapeutics is a well funded, clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In addition to AEG33773, a compound in Phase 1 clinical development for the treatment of pain associated with diabetic neuropathy, Aegera has three programs in clinical development for oncology indications. Details of our programs can be viewed on our Website at http://www.aegera.com.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
3. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
4. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
10. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
11. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016 Early-career researchers from ... Peru , Uganda and Yemen ... health and nutrition   Indonesia , ... and Yemen are being honored for their ... are also celebrated for mentoring young women scientists who are pursuing careers ...
(Date:2/10/2016)... and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined ... new vaccines and immunotherapies for infectious diseases and cancer. , The ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, has ... More than 1,600 participants have joined the PROMPT study, which seeks to advance ...
Breaking Biology Technology:
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... Unisys Corporation (NYSE: UIS ) today announced the implementation ... New York City , to help U.S. ... the United States using passports that are ... of the system at Dulles last year. The system will ... 2016. --> pilot testing of the system at ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):